Key Highlights:
- Eli Lilly (LLY, Financial) and Novo Nordisk (NVO) face share price declines due to policy decisions impacting obesity medication coverage.
- Analysts provide a positive outlook on Eli Lilly's stock, with a significant potential upside.
- GuruFocus metrics suggest a fair value for Eli Lilly with a promising upside.
The Trump administration's decision to not back the Biden administration's proposal for Medicare coverage of obesity medications caused a notable decline in the share prices of Eli Lilly (LLY) and Novo Nordisk (NVO). This decision has cast uncertainty over the future accessibility of weight loss drugs for millions of Americans.
Wall Street Analysts Forecast
Wall Street's analysts have weighed in with their one-year price targets for Eli Lilly and Co (LLY, Financial). According to 25 analysts, the average target price stands at $1,017.81, with expectations ranging from a high of $1,190.00 to a low of $800.00. This average target forecasts a potential upside of 37.88% from the current share price of $738.21. For more detailed projections, visit the Eli Lilly and Co (LLY) Forecast page.
Further supporting the optimistic outlook, the consensus recommendation from 29 brokerage firms places Eli Lilly and Co (LLY, Financial) at an average rating of 1.9, indicating an "Outperform" status. This rating is on a scale where 1 signifies a Strong Buy and 5 denotes a Sell.
Delving into GuruFocus estimates, the anticipated GF Value for Eli Lilly and Co (LLY, Financial) in the coming year is $1124.24. This figure suggests a considerable upside of 52.29% from the current price of $738.21. The GF Value represents GuruFocus' calculated fair value for the stock, derived from historical trading multiples, past business growth, and future performance projections. For more in-depth data, visit the Eli Lilly and Co (LLY) Summary page.
